Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
JAMA Netw Open. 2025 Mar 3;8(3):e250380. doi: 10.1001/jamanetworkopen.2025.0380. ABSTRACT IMPORTANCE: Nirsevimab, a long-acting monoclonal antibody, demonstrated efficacy against respiratory syncytial virus (RSV)-associated lower respiratory tract …